| Liquid biopsies come of age: towards implementation of circulating tumour DNA JCM Wan, C Massie, J Garcia-Corbacho, F Mouliere, JD Brenton, ... Nature Reviews Cancer 17 (4), 223-238, 2017 | 2310 | 2017 |
| Enhanced detection of circulating tumor DNA by fragment size analysis F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ... Science translational medicine 10 (466), eaat4921, 2018 | 875 | 2018 |
| Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies U Banerji, A O'Donnell, M Scurr, S Pacey, S Stapleton, Y Asad, ... Journal of Clinical Oncology 23 (18), 4152-4161, 2005 | 575 | 2005 |
| Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer CS Tan, D Gilligan, S Pacey The lancet oncology 16 (9), e447-e459, 2015 | 402 | 2015 |
| Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers R Plummer, G Attard, S Pacey, L Li, A Razak, R Perrett, M Barrett, ... Clinical cancer research 13 (20), 6187-6194, 2007 | 300 | 2007 |
| A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors S Pacey, RH Wilson, M Walton, MM Eatock, A Hardcastle, A Zetterlund, ... Clinical cancer research 17 (6), 1561-1570, 2011 | 227 | 2011 |
| A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma S Pacey, M Gore, D Chao, U Banerji, J Larkin, S Sarker, K Owen, Y Asad, ... Investigational new drugs 30, 341-349, 2012 | 160 | 2012 |
| Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with … JS de Bono, R Kristeleit, A Tolcher, P Fong, S Pacey, V Karavasilis, ... Clinical Cancer Research 14 (20), 6663-6673, 2008 | 137 | 2008 |
| Hsp90 inhibitors in the clinic S Pacey, U Banerj, I Judson, P Workman Molecular Chaperones in Health and Disease, 331-358, 2006 | 135 | 2006 |
| Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells N Gaspar, SY Sharp, S Pacey, C Jones, M Walton, G Vassal, S Eccles, ... Cancer research 69 (5), 1966-1975, 2009 | 131 | 2009 |
| Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers E Beddowes, J Spicer, PY Chan, R Khadeir, JG Corbacho, D Repana, ... Journal of Clinical Oncology 35 (16), 1778-1785, 2017 | 116 | 2017 |
| Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS–RAF mutations L Zimmer, F Barlesi, M Martinez-Garcia, V Dieras, JHM Schellens, ... Clinical Cancer Research 20 (16), 4251-4261, 2014 | 86 | 2014 |
| Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin UN Vaishampayan, AM Burger, EA Sausville, LK Heilbrun, J Li, ... Clinical Cancer Research 16 (14), 3795-3804, 2010 | 66 | 2010 |
| A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma PE Hall, R Lewis, N Syed, R Shaffer, J Evanson, S Ellis, M Williams, ... Clinical Cancer Research 25 (9), 2708-2716, 2019 | 59 | 2019 |
| Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA I Hudecova, CG Smith, R Hänsel-Hertsch, CS Chilamakuri, JA Morris, ... Genome research 32 (2), 215-227, 2022 | 52 | 2022 |
| Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial S Pacey, MJ Ratain, KT Flaherty, SB Kaye, L Cupit, EK Rowinsky, C Xia, ... Investigational new drugs 29, 481-488, 2011 | 52 | 2011 |
| A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced … A Greystoke, S Blagden, AL Thomas, E Scott, G Attard, R Molife, L Vidal, ... Annals of oncology 17 (8), 1313-1319, 2006 | 46 | 2006 |
| A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo LD Cassidy, ARJ Young, PA Pérez-Mancera, B Nimmervoll, A Jaulim, ... Autophagy 14 (7), 1256-1266, 2018 | 40 | 2018 |
| Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development D Sarker, S Pacey, P Workman Biomarkers in medicine 1 (3), 399-417, 2007 | 32 | 2007 |
| Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers S Pacey, D Rea, N Steven, C Brock, N Knowlton, N Shand, K Hazell, ... Journal of Clinical Oncology 22 (14_suppl), 3120-3120, 2004 | 30 | 2004 |
